Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments.
Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target.
Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months.
Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise.
The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).
Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target.
Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months.
Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise.
The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).
Location: United Kingdom, England, London
Employees: 11-50
Total raised: $120M
Founded date: 2022
Investors 4
| Date | Name | Website |
| 06.10.2022 | Brandon Ca... | brandoncap... |
| - | Forbion | forbion.co... |
| 12.06.2024 | TCG Crosso... | tcgcrossov... |
| 03.10.2022 | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.05.2024 | Series B | $120M | - |
Mentions in press and media 10
| Date | Title | Description |
| 10.09.2024 | Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki | 10 September 2024 London UK, 10 September 2024 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the appointment of ac... |
| 12.08.2024 | The endgame: 10 European startups aiming to defeat cancer | Cancer remains one of the most pressing global health challenges, claiming millions of lives each year and impacting countless more. Despite significant advancements in research and treatment, the fight against cancer demands continuous inn... |
| 04.06.2024 | Brandon Capital Announces Sixth Fund with A$270 million (US$180 million) Initial Close to Drive Life Science Innovation | MELBOURNE, Australia – 4 June 2024 – Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at A$270 million (US$180 million). ... |
| 21.05.2024 | Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline | - Financing led by TCGX, including new investment from BVF Partners, Lightspeed Venture Partners (Lightspeed) and Perceptive Advisors - Three first-in-class ADC assets funded through clinical proof of concept London UK, 21 May 2024 – Pheon ... |
| 21.05.2024 | Pheon Therapeutics Raises $120M in Series B Financing | Pheon Therapeutics, a Harpenden, near London, UK-based Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, closed a $120m Series B financing. The round was led by TCGX with par... |
| 21.05.2024 | Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline | London UK, 21 May 2024 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing ... |
| 28.09.2022 | Pheon Therapeutics Launches with $68M Series A | BOSTON, MA, Pheon Therapeutics (Pheon), an Antibody-Drug Conjugate (ADC) specialist, launched following the closing of a $68 million Series A financing. >> Click here for more funding data on Pheon Therapeutics >> To export ... |
| 28.09.2022 | Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics | Melbourne, Australia and London UK, 28 September 2022 –Brandon Capital, Australasia’s leading life science venture capital firm, is pleased to announce its leading role in the USD68m series A financing of Pheon Therapeutics (Pheon), that ha... |
| 28.09.2022 | Pheon Therapeutics Raises $68M in Series A Financing | Pheon Therapeutics, a London, UK-based Antibody Drug Conjugate company developing a pipeline of monotherapies for targets and/or with payloads, raised $68M in Series A funding. The round was led by Brandon Capital, Forbion and Atlas Venture... |
| - | Pheon Therapeutics | “Pheon Therapeutics – Developing next generation ADCs for a wide range of hard-to-treat cancers” |